Optimal delivery of minocycline to the brain: Implication for human studies of acute neuroprotection

Susan C. Fagan, David J. Edwards, Cesar V. Borlongan, Lin Xu, Ankur Arora, Giora Feuerstein, David C. Hess

Research output: Contribution to journalArticle

107 Scopus citations


Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.

Original languageEnglish (US)
Pages (from-to)248-251
Number of pages4
JournalExperimental Neurology
Issue number2
StatePublished - Apr 1 2004



  • Blood-brain barrier
  • Dose
  • Intraperitoneal
  • Minocycline
  • Neuroprotection
  • Pharmacokinetics

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this